Single cell RNA-sequencing of Ewing sarcoma tumors demonstrates transcriptional heterogeneity and clonal evolution

IF 10.2 1区 医学 Q1 ONCOLOGY Clinical Cancer Research Pub Date : 2025-03-03 DOI:10.1158/1078-0432.ccr-24-2040
Andrew Goodspeed, Avery Bodlak, Alexis B. Duffy, Sarah Nelson-Taylor, Naoki Oike, Timothy Porfilio, Ryota Shirai, Deandra Walker, Amy Treece, Jennifer Black, Nathan Donaldson, Carrye Cost, Tim Garrington, Brian Greffe, Sandra Luna-Fineman, Jenna Demedis, Jessica Lake, Etienne P. Danis, Michael Verneris, Daniel L. Adams, Masanori Hayashi
{"title":"Single cell RNA-sequencing of Ewing sarcoma tumors demonstrates transcriptional heterogeneity and clonal evolution","authors":"Andrew Goodspeed, Avery Bodlak, Alexis B. Duffy, Sarah Nelson-Taylor, Naoki Oike, Timothy Porfilio, Ryota Shirai, Deandra Walker, Amy Treece, Jennifer Black, Nathan Donaldson, Carrye Cost, Tim Garrington, Brian Greffe, Sandra Luna-Fineman, Jenna Demedis, Jessica Lake, Etienne P. Danis, Michael Verneris, Daniel L. Adams, Masanori Hayashi","doi":"10.1158/1078-0432.ccr-24-2040","DOIUrl":null,"url":null,"abstract":"Purpose: Ewing sarcoma (EwS) is the second most common bone cancer in children, accounting for 2% of pediatric cancer diagnoses. Patients who present with metastatic disease at the time of diagnosis have a dismal prognosis, compared to the >70% 5-year survival of those with localized disease. Novel therapeutic approaches that can impact metastatic disease are desperately needed, as well as a deeper understanding of the heterogeneity of EwS tumors. Experimental Design: Here, we utilized single cell RNA-sequencing to characterize the transcriptional landscape of primary EwS tumors and surrounding tumor microenvironment (TME) in a cohort of seven untreated EwS patients, as well as in circulating tumor cells (CTCs). A potential CTC therapeutic target was evaluated through immunofluorescence of fixed CTCs from a separate cohort. Results: Primary tumor samples demonstrate a heterogenous transcriptional landscape with several conserved gene expression programs, including those composed of genes related to proliferation and EWS gene targets, which were found to correlate with overall survival. Copy-number analysis identified subclonal evolution within patients prior to treatment. Analyses of the immune microenvironment reveal an immunosuppressive microenvironment with complex intercellular communication within the tumor and immune cells. Single cell RNA-sequencing and immunofluorescence of CTCs at the time of diagnosis identified TSPAN8 as a potential therapeutic target. Conclusions: EwS tumors demonstrate significant transcriptional heterogeneity as well as a complex immunosuppressive microenvironment. This work evaluates several proposed targets which would warrant further exploration as novel therapeutic strategies.","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":"130 1","pages":""},"PeriodicalIF":10.2000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1078-0432.ccr-24-2040","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Ewing sarcoma (EwS) is the second most common bone cancer in children, accounting for 2% of pediatric cancer diagnoses. Patients who present with metastatic disease at the time of diagnosis have a dismal prognosis, compared to the >70% 5-year survival of those with localized disease. Novel therapeutic approaches that can impact metastatic disease are desperately needed, as well as a deeper understanding of the heterogeneity of EwS tumors. Experimental Design: Here, we utilized single cell RNA-sequencing to characterize the transcriptional landscape of primary EwS tumors and surrounding tumor microenvironment (TME) in a cohort of seven untreated EwS patients, as well as in circulating tumor cells (CTCs). A potential CTC therapeutic target was evaluated through immunofluorescence of fixed CTCs from a separate cohort. Results: Primary tumor samples demonstrate a heterogenous transcriptional landscape with several conserved gene expression programs, including those composed of genes related to proliferation and EWS gene targets, which were found to correlate with overall survival. Copy-number analysis identified subclonal evolution within patients prior to treatment. Analyses of the immune microenvironment reveal an immunosuppressive microenvironment with complex intercellular communication within the tumor and immune cells. Single cell RNA-sequencing and immunofluorescence of CTCs at the time of diagnosis identified TSPAN8 as a potential therapeutic target. Conclusions: EwS tumors demonstrate significant transcriptional heterogeneity as well as a complex immunosuppressive microenvironment. This work evaluates several proposed targets which would warrant further exploration as novel therapeutic strategies.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
尤文肉瘤肿瘤的单细胞 RNA 测序显示了转录异质性和克隆进化
目的:尤文氏肉瘤(EwS)是儿童中第二大常见的骨癌,占儿童癌症诊断的2%。诊断时出现转移性疾病的患者预后不佳,而局限性疾病患者的5年生存率为70%。迫切需要能够影响转移性疾病的新治疗方法,以及对EwS肿瘤异质性的更深入了解。实验设计:在这里,我们利用单细胞rna测序来表征7名未经治疗的EwS患者以及循环肿瘤细胞(ctc)的原发性EwS肿瘤和周围肿瘤微环境(TME)的转录景观。通过来自单独队列的固定CTC的免疫荧光来评估潜在的CTC治疗靶点。结果:原发性肿瘤样本显示出异质性转录景观,其中包括一些保守的基因表达程序,包括与增殖和EWS基因靶点相关的基因,这些基因与总体生存相关。拷贝数分析确定了治疗前患者的亚克隆进化。免疫微环境的分析揭示了肿瘤和免疫细胞内具有复杂细胞间通讯的免疫抑制微环境。诊断时ctc的单细胞rna测序和免疫荧光鉴定TSPAN8是一个潜在的治疗靶点。结论:EwS肿瘤具有显著的转录异质性和复杂的免疫抑制微环境。这项工作评估了几个建议的目标,这些目标将值得进一步探索作为新的治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Cancer Research
Clinical Cancer Research 医学-肿瘤学
CiteScore
20.10
自引率
1.70%
发文量
1207
审稿时长
2.1 months
期刊介绍: Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.
期刊最新文献
Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B41 Clinical Trial Validation. LM-101, an anti-SIRPα antibody, in patients with relapsed/refractory lymphoma and advanced head and neck cancer: an open-label, multicenter, phase 1 trial. Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer. The efficacy and safety of tislelizumab plus anlotinib as first-line treatment in advanced pulmonary sarcomatoid carcinoma: a single-arm phase II trial CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1